Evidence map›Paper›PMID 41557116›Full record

ArticleDrug delivery and translational research2026

Localized doxycycline delivery via polymeric nanoparticles anchored to electrospun PCL microfiber patch for MMP-2 inhibition in abdominal aortic aneurysm.

Carles Bofill-Bonet, Germán Febas, Margalida Artigues, Inés Moreno-Jiménez, Noemí Balà, Jordi Martorell, Salvador Borrós, Cristina Fornaguera

Abstract read
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Carles Bofill-BonetInstitut Químic de Sarrià (IQS), Universitat Ramon Llull (URL), Via Augusta 390, 08017, Barcelona, Spain.ORCID http://orcid.org/0000-0002-1820-5982
Germán FebasAortyx SL, Teia, Spain.ORCID http://orcid.org/0000-0001-5432-2863
Margalida ArtiguesInstitut Químic de Sarrià (IQS), Universitat Ramon Llull (URL), Via Augusta 390, 08017, Barcelona, Spain.ORCID http://orcid.org/0000-0001-8599-980X
Inés Moreno-JiménezAortyx SL, Teia, Spain.ORCID http://orcid.org/0000-0002-0717-3671
Noemí BalàAortyx SL, Teia, Spain.
Jordi MartorellInstitut Químic de Sarrià (IQS), Universitat Ramon Llull (URL), Via Augusta 390, 08017, Barcelona, Spain.ORCID http://orcid.org/0000-0002-2043-2762
Salvador BorrósInstitut Químic de Sarrià (IQS), Universitat Ramon Llull (URL), Via Augusta 390, 08017, Barcelona, Spain. salvador.borros@iqs.url.edu.ORCID http://orcid.org/0000-0002-4003-0381
Cristina FornagueraInstitut Químic de Sarrià (IQS), Universitat Ramon Llull (URL), Via Augusta 390, 08017, Barcelona, Spain. cristina.fornaguera@iqs.url.edu.ORCID http://orcid.org/0000-0002-7014-3213

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2021 SGR 00537Agència de Gestió d'Ajuts Universitaris i de Recerca ACE05322000116Agència de Gestió d'Ajuts Universitaris i de Recerca ICREA Acadèmia 2024Agencia Estatal de Investigación AC22/00042Fundación Científica Asociación Española Contra el Cáncer TRNSC213882FORNMinisterio de Ciencia, Innovación y Universidades MCIN/AEI/10.13039/501100011033/FEDERMinisterio de Ciencia, Innovación y Universidades PID2021-125910OB-I00Ministerio de Ciencia, Innovación y Universidades RTC2019-007260-1Ministerio de Ciencia, Innovación y Universidades UE
6 · The paper itself

Abstract

Doxycycline (DOXY) is a well-established antibiotic that has recently shown potential in inhibiting matrix metalloproteinase-2 (MMP-2), a key enzyme involved in the progression of abdominal aortic aneurysms (AAA). However, the controlled delivery of DOXY to the aneurysm site, with sustained release and minimal systemic exposure, remains a critical challenge in therapeutic development. To address this, we developed a targeted drug delivery platform based on polymeric nanoparticles (NPs), prepared from water-in-oil-in-water nano-emulsions, encapsulating DOXY and are covalently attached to electrospun ε-poly(caprolactone) (ε-PCL) microfibers. This system was designed to enable local, sustained drug release in the inner wall of aorta while preserving the mechanical properties of the aortic wall. The ε-PCL electrospun microfibers from the patch were first functionalized using oxygen cold plasma treatment, creating free radicals that enabled covalent bonding with chemical groups on the outer layer of DOXY-loaded poly(lactic-co-glycolic acid) (PLGA) NPs. This strategy allowed for robust immobilization of the NPs onto the microfibers surface, forming a composite system capable of localized and controlled drug release over time. Unlike traditional delivery approaches, this method ensures site-specific action of DOXY directly at the aneurysmal tissue, minimizing systemic circulation and reducing off-target toxicity. The platform not only provides a stable drug reservoir but also offers intrinsic biomechanical reinforcement, which is critical in AAA condition. This innovative delivery system represents a significant advance in the localized treatment of vascular disorders. It offers a biocompatible, biodegradable, and precisely targeted therapeutic approach, with potential to reduce the need for surgical intervention and limits the adverse effects associated with systemic drug administration. HIGHLIGHTS: - Novel polymeric Doxycycline loaded PLGA nanoparticles have been developed and result efficacious within hMMP-2 mitigation and collagen degradation in Abdominal Aortic Aneurysm condition. - Doxycycline loaded polymeric nanoparticles were covalently anchored to ε-Poly(caprolactone) electrospun microfibers via cold plasma-induced radical grafting, enabling sustained drug release for over 12 days. - Doxycycline-loaded nanoparticles released from microfibers efficaciously mitigate hMMP-2 in human in vitro models of Abdominal Aortic Aneurysm. - Doxycycline released from drug-coated electrospun ε-Poly(caprolactone) although efficacious does not allows time-control.

Indexed as

Aortic Aneurysm, AbdominalDoxycyclineMatrix Metalloproteinase InhibitorsNanoparticlesPolyestersAnimalsDelayed-Action PreparationsDrug Delivery SystemsDrug LiberationHumansMatrix Metalloproteinase 2Polyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerDelayed-Action PreparationsDoxycyclineMatrix Metalloproteinase 2Matrix Metalloproteinase InhibitorspolycaprolactonePolyestersPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerAbdominal aortic aneurysm therapiesDoxycycline encapsulationNanoparticle anchored nanofibersPolymeric nanoparticlesWater-In-Oil-In-Water nano-emulsions

Identifiers

PMID41557116
PMCPMC13346288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.